EC to Investigate Aspen Pharma Cancer Drug Price Hikes
Genetic Engineering & Biotechnology News (GEN) | May 15, 2017
The European Commission said today that it launched a formal investigation into whether Aspen Pharma has abused its dominant market position in cancer treatments to overcharge for five drugs—the first time the EC has ever probed concerns about excessive pricing practices in the pharmaceutical industry.